Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia

Hideaki Katagiri1 Bio-Medicines, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, JapanCorrespondence[email protected]

Masanori Taketsuna2 Statistical Sciences, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan

Shinpei Kondo3 Post Marketing Study Management, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan

Kenta Kajimoto4 Scientific Communications, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan

Etsuko Aoi5 Global Patient Safety Japan, Quality and Patient Safety, Eli Lilly Japan K.K., Kobe, Japan

Yuka Tanji1 Bio-Medicines, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.